2024-08-22
1. Summary of the week
8月16日到22日，全球医药市场共完成了5项授权和合作协议，中国医药市场占了4项，包括3项出海交易和1项国内交易。其中最引人注目的交易是默沙东行使独家选择权，引进科伦博泰一临床前双抗资产，首付3750万美元。此外，普众发现将一款ADC资产授权给Adcendo。
在全球范围内，仅签署了一项协议，SciSparc与Polyrizon就前者的临床前资产THX-160达成授权交易。
Between August 16 and 22, a total of five licensing and cooperation deals were signed globally, with four of them occurring within the China Biotech Industry. Notably, Kelun-Biotech and Merck & Co. entered into an out-licensing agreement for a pre-clinical stage asset, involving an upfront payment of $37.5 million. Additionally, Multitude Therapeutics and Adcendo secured an out-licensing deal for an Antibody-Drug Conjugate (ADC).
On the global stage, only one other licensing deal was reported, involving SciSparc and Polyrizon for the pre-clinical stage asset THX-160.
2. Licensing Deals
2a. China section
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
5. 2019-2023 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit http://www.yafocapital.com
ACCESS CHINA
Event Name:
2024-09 药通中国秋季路演，线上&云南
2024-09 ACCESS CHINA Autumn Roadshow, Virtual & Yunnan
2025-01 药通中国论坛@JPM，线上&旧金山
2025-01 ACCESS CHINA @ JPM Week, Virtual & San Francisco
BioToChina.org 